Referenser:
1. Wright T, Bosch X, Franco F, et al. HPV vaccines and
screening in the prevention of cervical cancer; conclusions from a 2006
workshop of international experts. Vaccine 2006; 24S3: 251-261.
2. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human
papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst
1995; 87: 796-802.
3. Muñoz N, Castellsagué X, Berrington de Gonzålez A, et al.
HPV in the etiology of human cancer. Vaccine 2006; 24S3: 1-10.
4. Frisch M, Smith E, Grulich A, et al. Cancer in a
population based cohort of men and women in registered homosexual partnerships.
Am J Epidemiol 2003; 157: 966-972.
5. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization
with virus-like particles from cottontail rabbit papillomavirus (CRPV) can
protect against experimental CRPV infection. J Virol 1995; 69: 3959-3963.
6. Suzich JA, Ghim S, Palmer-Hill FJ, et al. Systemic
immunization with papillomavirus L1 protein completely prevents the development
of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92: 11553-11557.
7. Kirnbauer R, Chandrachud L, O`Neil B, et al. Virus-like
particles of Bovine Papillomavirus type
4 in prophylactic and therapeutic immunization.
Virology 1996; 219: 37-44.
8. Villa LL, Costa RL, Petta CA, et al. Prophylactic
quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like
particle vaccine in young women: a randomised double-blind placebo-controlled
multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271-278.
9. Harper DM, Franco EL, Wheeler CM, et al. Sustained
efficacy of up to 4.5 years of a bivalent L1-virus-like particle vaccine
against human papillomavirus types 16 and 18; follow-up from a randomised
control trial. Lancet 2006;367: 1247-1255.
10. Waller J, Marlow
LA, Wardle J. MotherÂŽs attitudes towards preventing cervicalcancer
through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol
Biomarkers Prev. 2006; 15: 1257-1261.
11. Slomovitz BM, Sun CC, Frumovitz M, et al. Are women
ready for the HPV vaccine? Gynecol Oncol 2006; 103: 151-154.
12. Villa LL, Ault KA, Giuliano AR, et al. Immunologic
responses following administration of a vaccine targeting human papillomavirus
types 6, 11, 16 and 18. Vaccine 2006; 24: 5571- 5583.